Understanding precisely which molecular actors translate DNA damage into permanent mutations is one of cancer biology's most consequential puzzles — because the answer determines both who develops cancer after carcinogen exposure and why some chemotherapy regimens inadvertently seed secondary tumors. New mechanistic work published in PNAS identifies a specific error-prone DNA polymerase as a key culprit in two clinically important mutation contexts: tobacco smoke exposure and platinum-based chemotherapy.
The research centers on DNA polymerase iota (Pol ι), a translesion synthesis enzyme that steps in when the replication machinery stalls at damaged DNA bases. Using cellular smoking models, the investigators demonstrate that Pol ι preferentially generates cytosine-to-thymine (C>T) substitutions — a mutation class already well-catalogued in lung cancer genomics. Critically, the team also links Pol ι activity to SBS31, a single base substitution signature associated with prior platinum chemotherapy exposure, tying a clinically administered drug to a specific enzymatic mechanism that can generate genomic instability in treated patients.
This finding matters for several converging reasons. Translesion synthesis polymerases have historically been under-explored as therapeutic targets compared to upstream DNA damage response kinases, yet they sit at the precise decision point between DNA damage and permanent mutation. By pinpointing Pol ι as mechanistically active in both environmental (smoking) and iatrogenic (platinum drug) mutation contexts, this work raises the possibility that Pol ι inhibition could reduce mutagenic burden in high-risk populations — smokers undergoing chemotherapy being an obvious overlap group. That said, important caveats apply: cellular models, however well-constructed, do not fully recapitulate tumor microenvironment complexity or inter-individual variation in Pol ι expression. The SBS31 signature link is especially noteworthy given ongoing debate about which patients treated with cisplatin or oxaliplatin accumulate the highest secondary mutation risk. Whether Pol ι inhibition is pharmacologically tractable and tolerable remains entirely unresolved. This is mechanistically precise, potentially paradigm-refining work, but translational distance remains substantial.